The aim of the present work was to discuss, from the regulatory point of view, the recent developments in clinical trial authorization in Eastern European countries. The study was based on a questionnaire sent to drug regulatory agencies or clinical experts in 12 countries as well as on the author's personal experiences. Very fast changes in ethical approval, good clinial practice (GCP) application, and its compliance monitoring could be observed, especially in countries associated with the European Union. The impact of the newly accepted International Conference on Hamonization GCP is also likely in Eastern Europe.
PaálTL. East European Perspectives on the European Community's Registration Procedure. Reg Affairs.1990;2:85–114.
2.
PaálTL. Implementation of “Good Practices” in Eastern Europe. In: DentN. ed. Implementing international Good Practices.Buffalo Grove: Interpharm Press; 1993:235–248.
3.
PaálTL. GCP—Current Events in Eastern Europe. In: BennetP. ed. Good Clinical Practice and Ethics in European Drug Research.Bath, England: Bath University Press; 1994:37–47.
4.
PaálTL. An Updated Situation of the Current Compliance within Hungary and other Eastern and Central European Countries. In: DentN.Good Research Practices.Oxford: Butterworth and Heinemann; 1996.
5.
DzúrikR. How to organize Clinical Trials in Czechoslovakia. App Clin Trials.1992;1:42–44.
6.
KotTCzarneckiA. Registration in Poland. Reg Aff J.1995;6:14–21.
7.
Anon. Russia Ideal for the Adventuresome. World Pharm Rep.1992;1:5.
8.
PozsonyiS. Decentralized Management of Clinical Research in Central and Eastern Europe. App Clin Trials.1994;4:50–53.
9.
RagoL. Regulatory Affairs in Estonia. Reg Aff J.1994;5:1004–1008.
10.
LoranBRudakovAKolesovSWhite-GuayB. Registration in the Russian Federation. Reg Aff J.1996;7:552–559.
